One of the characteristics of gliomas is a decrease in the expression of connexin43, a protein that forms gap junctions. Restoring connexin43 expression in glioma cells reduces their exacerbated rate of cell growth, although it is not yet known how connexin43 modifies the expression of genes involved in cell proliferation. Here, we show that restoring connexin43 to C6 glioma cells impedes their progression from G0/G1 to the S phase of the cell cycle by reducing retinoblastoma phosphorylation and cyclin E expression through the upregulation of p21 and p27. Interestingly, connexin43 diminishes the oncogenic activity of c-Src exhibited by glioma cells. By studying a Tyr247 and Tyr265 mutant connexin43, we show that these residues are required for connexin43 to inhibit c-Src activity and cell proliferation. In conclusion, by acting as a substrate of c-Src, connexin43 reduces its oncogenic activity and decreases the rate of glioma cell proliferation, potentially an early step in the antiproliferative effects of connexin43. Although c-Src is known to phosphorylate connexin43, this study provides the first evidence that connexin43 can also inhibit c-Src activity.
Introduction
Connexin43 (Cx43), the most abundant connexin in mammals, is an integral membrane protein widely expressed in different tissues. In the CNS, Cx43 is strongly expressed in astrocytes where it exerts a variety of important biological functions. Cx43 assembles to form gap junction channels that facilitate the behavior of astrocytes as metabolic networks (Rouach et al., 2008) . Cx43 also forms hemichannels responsible for the interchange of molecules and signals between a cell and its extracellular medium (for a review: Bennett et al., 2003) . Furthermore, the intracellular carboxy tail of Cx43 (Cx43CT) interacts with a large number of signaling and scaffolding proteins (Giepmans, 2006; Herve et al., 2007) , thereby regulating cell functions such as cell adhesion, migration and proliferation (Bates et al., 2007 ; for a review: Kardami et al., 2007; Prochnow and Dermietzel, 2008; Cina et al., 2009) . Since it was first identified (Loewenstein and Kanno, 1966) , the role of gap junctions in regulating cell proliferation has been widely studied, although there are still several aspects of this process that remain to be elucidated. Cx43 is believed to participate in proliferation since it is subjected to several modifications during the cell cycle (Lampe and Lau, 2004; Solan and Lampe, 2009 ), such as phosphorylation by CDK1 during mitosis (Kanemitsu et al., 1998) . In addition, the rate of astrocyte cell proliferation is reduced in Cx43 KO mice (Naus et al., 1997) . On the other hand, a decrease in Cx43 expression is usually observed in gliomas, the levels of which are inversely correlated with the degree of malignancy (Shinoura et al., 1996; Huang et al., 1999; Soroceanu et al., 2001; Pu et al., 2004) . Interestingly, restoring Cx43 in glioma cells reduces their rate of proliferation (Zhu et al., 1991; Huang et al., 1998) .
The mechanism by which Cx43 alters the rate of glioma cell proliferation is not fully understood. It has been shown that Cx43 modifies the expression of several genes involved in cell cycle regulation, such as p21 and p27, two cyclin dependent kinase inhibitors (CKI) that inhibit cell cycle progress in different tumor cells (Koffler et al., 2000; Zhang et al., 2001) . The increase in p27 is due to a reduction in its degradation that is promoted by a decrease in Skp2, a protein that regulates p27 ubiquitination (Zhang et al., 2003) . In addition, the dose-dependent upregulation of CCN1/Cyr61 and CCN3/NOV by Cx43 could explain why different levels of Cx43 can exert different effects on cell proliferation and migration (Sin et al., 2008) . Thus, low levels of Cx43 promotes the expression of CCN1, which induces the growth and motility of glioma cells, while high levels of Cx43 preferentially upregulate CCN3, which acts as a tumor suppressor and reduces the rate of cell growth (Fu et al., 2004) . However, how Cx43 promotes changes in the expression of genes involved in cell proliferation is not yet clear.
The Cx43CT is known to interact with c-Src, a nonreceptor tyrosine kinase that can regulate cell proliferation. Activated c-Src phosphorylates Cx43 on critical tyrosine residues, Tyr247 and Tyr265, and this event reduces intercellular communication and Cx43 internalization (Swenson et al., 1990; Giepmans et al., 2001; Lin et al., 2001; Lampe and Lau, 2004; Pahujaa et al., 2007; Gilleron et al., 2008) . Since one of the characteristics of gliomas is the high oncogenic activity of c-Src (Du et al., 2009 ), we have investigated the possible participation of c-Src in the antiproliferative effect of Cx43 on glioma cells.
Results
Connexin43 arrests the cell cycle progression of glioma cells from G0-G1 to S phase Although it is well known that restoring Cx43 to glioma cells decreases their rate of proliferation (Zhu et al., 1991; Naus, 2002) , we set out to gain a deeper insight into the molecular mechanisms responsible for this effect. Accordingly, we stably transfected C6 glioma cells with Cx43 (C6-Cx43) or with the empty vector (C6-Ires), and the expression of Cx43 was analyzed by western blot in a selection of Cx43 transfected clones numbered from 1 to 9 (Figure 1a ). Clones 4, 6, 7, 8 and 9 expressed Cx43 more strongly than C6 and C6-Ires, and clone number 7 expressed Cx43 most strongly. Indeed, immunocytochemistry revealed that most of the clone 7 cells stably expressed Cx43 (82.83% ± 1.39, n ¼ 6; Figure 1b) . In this line, Cx43 expression remained stable at least over 4 passages (Supplementary Figure  S1 ). In accordance with the expression of Cx43, the transfected clones 4 and 9 had greater gap junctional permeability than the C6-Ires cells, and clone number 7 exhibited the highest level of gap junctional coupling (Figure 1c ). When the rate of cell growth was analyzed, we found that the level of Cx43 expression was inversely correlated with the rate of cell growth (Figure 1d ), as indicated previously (Zhu et al., 1991) . Since Cx43 expression, location and gap junctional intercellular communication (GJIC) in clone number 7 was comparable to that of astrocytes studied in primary cultures, and these cells have a slow rate of proliferation, clone number 7 was selected and used in further studies, unless otherwise specified.
Having established that restoring Cx43 reduces glioma cell proliferation in our experimental model, we assessed which phases of the cell cycle were modified by the presence of Cx43 by estimating the percentage of cells in each different cell cycle phases by flow cytometry (Figure 2 ). When asynchronous cells were analyzed, we found that the presence of Cx43 decreased the percentage of cells found in S-phase by about 53%, with a concomitant yet not significant increase in those in G0/ G1 (Figure 2a ). To determine whether the transit from G1 to S phase was affected in C6-Cx43 cells, they were synchronized in G0/G1 and the cell cycle stage was analyzed at different times after release (Figure 2b ). Our results show that serum removal over 60 h arrested most of the cells in G0/G1 (Figure 2b ) without affecting cell viability (Supplementary Figure S2) . Figure 2b shows that C6-Ires completed their cell cycle in about 16 h. Thus, about 50% of the cells had left the G0/G1 phase 10 h after the re-entry into the cycle and were in S-phase. Some 4 h later, most of the cells were in G2/M and at 16 h, the percentage of cells found in G0/G1 began to increase, indicating that the cell cycle had been completed. However, when the C6-Cx43 cell cycle was analyzed, we found that the percentage of cells found in G0/G1 did not decrease until after 14 h, with only a slight reduction of about 5%. The cell cycle in C6-Cx43 cells was followed for 34 h until the percentage of cells in G0/G1 cells began to increase. In fact, the percentage of C6-Cx43 cells in G0/G1 never dropped below 64% (Supplementary Figure S3) . To investigate whether the presence of Cx43 modified the transition from G2/M to G0/G1, these cells were synchronized in G2/M. However C6-Cx43 did not show problems in the transition from G2/M to G0/G1 (Supplementary Figure S4) .
Connexin43 prevents pRb phosphorylation and the upregulation of cyclin E Since Cx43 appears to arrest the glioma cell cycle in G0/ G1, we investigated the cell cycle regulators that might be involved in this antiproliferative effect. It has been reported that Cx43 promotes the upregulation of p27 and p21 (Zhang et al., 2001) , which inhibit the activity of CDK and impair the transition through the cell cycle. Indeed, our results show that the expression of both p21 and p27 is augmented in C6-Cx43 when compared with C6-Ires at all points of the cell cycle analyzed (Figures  3a and b) . We previously found that inhibiting GJIC in astrocytes upregulates cyclin D1 and D3 expression (Tabernero et al., 2006; Herrero-Gonzalez et al., 2009) , which are required for CDK4/6 activity and therefore, for the early events in the transition from the G0/G1 to S-phase of the cell cycle. Surprisingly, our results show that the expression of cyclins D1 and D3 was also upregulated by the presence of Cx43 in glioma cells. Indeed, cyclin D1 was more strongly expressed by C6-Cx43 than by C6-Ires at all times analyzed (Figure 3c ), and the expression of cyclin D3 was stronger in C6-Cx43 at all the times analyzed except between 10 and 14 h, when it was expressed in an equivalent manner (Figure 3d ). CDK4/6 regulates the cell cycle by phosphorylating pRb. Since both activators (cyclins D1 and D3) and inhibitors (p21 and p27) of CDK4/6 are upregulated by the presence of Cx43, we investigated the final balance of these molecules by analyzing the ratio between phosphorylated (pRb-P) and unphosphorylated pRb (pRb-NP: Figure 3e ). As expected for proliferative cells, the pRb-P/pRb-NP ratio increased gradually during the cell cycle in C6-Ires, however in C6-Cx43 this ratio remained high. Indeed, since it was not modified at any time point analyzed, this ratio was lower in C6-Cx43 than in C6-Ires from 10 h after re-entry into the cycle until the end of the cell cycle.
Phosphorylation of pRb causes the release of E2F, a transcription factor for several genes required for the transition from G1 to S-phase of the cell cycle (Sherr, 1996) . Among these genes is cyclin E that binds to and activates CDK2, which is in turn required for the cell to pass from G1 to S-phase (Ohtani et al., 1995; Geng et al., 1996) . Our results show that cyclin E was strongly upregulated after 10 h in C6-Ires, the point at which cells pass from G1 to S-phase of the cell cycle, and that it remained high for at least 4 h. However, the presence of Cx43 delayed the upregulation of cyclin E and strongly diminished the duration of this upregulation. Accordingly, in C6-Cx43 the levels of cyclin E were not upregulated at 10 h as occurred in C6-Ires and instead, the levels remained lower than in C6-Ires until 14 h after re-entry into the cycle. From then onwards, the levels of cyclin E did not differ significantly between C6-Ires and C6-Cx43 (Figure 3f ).
Connexin43 inhibits c-Src activity
Cx43 interacts with several proteins that could mediate its effect on cell cycle progression (Giepmans, 2 and the number of living cells was followed for 7 days by a MTT assay. The results are means ± s.e.m. (n ¼ 4) and they are expressed as the percentages of the higher value of absorbance found in C6 cells (6th day).
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S Herrero-González et al 2006; Herve et al., 2007) . One such protein is c-Src, a non-receptor tyrosine kinase that is very active in gliomas (Du et al., 2009) and that is known to be oncogenic (Thomas and Brugge, 1997) . Autophosphorylation at Tyr-416 activates c-Src (Kmiecik and Shalloway, 1987; Xu et al., 1997 ) and therefore, we followed c-Src phosphorylated at Tyr-416 (Y416 c-Src) to monitor the activity of c-Src. While the total amount of c-Src was not modified, the presence of Cx43 diminished the activity of c-Src by more than 60% in glioma cells (Figure 4a ). This decrease in c-Src activity promoted by Cx43 in glioma cells was also confirmed by immunocytochemistry ( Figure 4b ) and in fact, we found that the active form of c-Src was mainly located in the nucleus of C6 glioma cells, an unusual location previously reported in other tumor cells (David-Pfeuty et al., 1993; Campbell et al., 2008) . To confirm the down-regulation of c-Src activity promoted by Cx43, Y416 c-Src was followed throughout the cell cycle ( Figure 4c ). Our results show that the activity of c-Src increased gradually in C6-Ires cells from 10 h until the end of the cell cycle. However, in C6-Cx43 cells the activity of c-Src decreased when the cells should enter S-phase (10 h) and its activity remained lower than that found in C6-Ires until the end of the cell cycle. Finally, the activity of c-Src was analyzed in C6-Cx43 cells after silencing Cx43 expression by siRNA ( Figure 4d ). Our results show that the knock-down of Cx43 in C6-Cx43 reverted the effect on c-Src activity. Thus, while the levels of total c-Src were not modified, the levels of Y416 c-Src were increased by about 45% in C6-Cx43 transfected with Cx43-siRNA ( Figure 4d ).
Connexin43 lacking its c-Src phosphorylation sites does not inhibit glioma cell proliferation
Not only does c-Src phosphorylate Cx43 at Tyr247 and Tyr265, but c-Src also preferentially binds to Cx43 phosphorylated on these residues (Giepmans et al., 2001; Lin et al., 2001) . To determine whether these residues were involved in the effects of Cx43 on c-Src activity, a double Cx43 mutant was constructed in which Tyr247 and Tyr265 were replaced by nonphosphorylable phenylalanines (Figure 5a ). After stably transfecting glioma cells with this construct, two clones were selected (C6-Cx43Y247F/Y265F 1 and 2) and the presence of Cx43 was confirmed by western blot (Figure 5b ). These clones expressed Cx43 and also exhibited GJIC when assessed by scrape loading (Figure 5c ). It should be noted that the levels of Cx43 expression and GJIC found in C6-Cx43Y247F/Y265F clones 1 and 2 were lower than those found in C6-Cx43 clone 7, and therefore we also compared these mutant cells with C6-Cx43 clones 4 and 9 (Figure 1c) , that expressed similar levels of Cx43 and displayed similar GJIC to that found in C6-Cx43Y247F/Y265F clones 1 and 2 ( Figure 5 ). Interestingly, this mutant Cx43 did not reduce the activity of c-Src in the same way that Cx43 did (Figure 6a ). Indeed, while the active form of c-Src was decreased in C6-Cx43 when compared with C6-Ires (by 55, 30 and 28% in clones 7, 4 and 9, respectively), this Connexin43 inhibits c-Src S Herrero-González et al reduction was not observed in C6-Cx43Y247F/Y265F clones 1 and 2. In addition, we analyzed the levels of c-Src phosphorylated at Tyr-527 (Y527 c-Src), the inactive form of c-Src. Our results show that the levels of Y527 c-Src were increased in the three clones expressing Cx43 when compared with C6-Ires (by about 60, 46 and 30%, in clones 7, 4 and 9, respectively), while there were no significant differences in clones 1 and 2 that express the mutant Cx43. Nevertheless, the total amount of c-Src was similar in all these glioma cells (Figure 6a) . Significantly, the mutant Cx43 did not reduce the rate of glioma cell proliferation (Figure 6b) . Thus, the growth curves of Cx43Y247F/Y265F clones 1 and 2 were very similar to that found for C6-Ires and they were steeper than those obtained with C6-Cx43 cells clones 4, 7 and 9 (Figures 1d and 6b) . Accordingly, the mutant Cx43 also failed to upregulate the expression of cyclins D1 and D3, p21 and p27, in the way that Cx43 did (Figure 6c and Supplementary Figure S5A) .
As indicated above, Cx43 prevented the upregulation of cyclin E when cells should pass from G1 to S-phase (that is, 10 h after synchronization in G0/G1: Figure 3) . Thus, when the levels of cyclin E were analyzed 10 h after synchronization we found that Cx43 reduced the expression of cyclin E by about 50% while the mutant Cx43 appeared to have no effect on the expression of Figure 3 Effect of restoring Cx43 on p21, p27, cyclin D1, cyclin D3, cyclin E expression and retinoblastoma phosphorylation. C6-Ires and C6-Cx43 were synchronized in G0/G1 and then released. The expression of different cell cycle regulators was analyzed by western blots and quantified at the times indicated. The results are the means ± s.e.m. (n ¼ 6) and they are expressed as percentages of the highest level found. (a) p21, the highest levels were found in C6-Cx43 at 10 h. (b) p27, the highest levels were found in C6-Cx43 at 0 h. (c) Cyclin D1, the highest levels were found in C6-Cx43 at 18 h. (d) Cyclin D3, the highest levels were found in C6-Cx43 at 16 h. (e) Western blot and quantification of the ratio of phosphorylated (pRb-P) and non phosphorylated pRb (pRb-NP). (f) Cyclin E, the highest levels were found in C6-Ires at 13 h. Values were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
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S Herrero-González et al Connexin43 inhibits c-Src S Herrero-González et al this cyclin (Figure 6d ). In addition, the upregulation of CKIs like p27 promoted by Cx43 10 h after synchronization in G0/G1 was not observed in cells transfected with the mutant Cx43, where the p27 levels were retained below those of the controls (Figure 6d ). Together, our results indicate that restoring Cx43 in glioma cells inhibits the activity of c-Src and this effect relies on residues Tyr247 and Tyr265 located in the Cx43CT (Figure 5a ). To confirm these results, nonmutated Cx43CT was transfected in glioma cells expressing Cx43 mutated on Tyr247 and Tyr265 and the activity of c-Src was monitored. Cells expressing Cx43CT plus the mutant Cx43 exhibited lower c-Src activity than those expressing the mutant Cx43 (Figure 6e ), indicating that the Cx43CT rescued the phenotype promoted by mutant Cx43. The expression of Cx43CT was followed by RT-PCR and western blot (Supplementary Figures  S5B and C) .
Discussion
A feature of several tumors is the reduction in connexin expression and in GJIC (Yamasaki et al., 1999) , and 
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S Herrero-González et al gliomas in particular downregulate Cx43, the expression of which is inversely correlated with the degree of malignancy (Shinoura et al., 1996; Huang et al., 1999; Soroceanu et al., 2001; Pu et al., 2004) . Restoring Cx43 expression in gliomas reduces the exacerbated rate of proliferation (Zhu et al., 1991; Huang et al., 1998) 
and
Connexin43 inhibits c-Src S Herrero-González et al thus, we sought to gain deeper insight into the molecular mechanisms involved in the antiproliferative effect of Cx43 in glioma cells. In this study we show that restoring Cx43 to glioma cells decelerates the passage of cells from G0/G1 to the S phase of the cell cycle. Among the factors responsible for this effect is the reduced expression of cyclin E promoted by Cx43. Indeed, Cx43 delays and reduces the upregulation of cyclin E, a step required for the passage of cells from the G1 to S phase. Concomitantly, Cx43 prevents the increase in pRb phosphorylation that occurs in C6 glioma cells upon entering S-phase. Since the phosphorylation of pRb releases E2F, a transcription factor implicated in cyclin E expression (Geng et al., 1996) , the reduction in pRb phosphorylation could provoke a decrease in cyclin E. Moreover, pRb is phosphorylated by CDKs, which are inhibited by several CKIs such as p21 and p27. Since Cx43 upregulates p21 and p27 (results herein and Zhang et al., 2003) this effect of Cx43 might reduce pRb phosphorylation and prevent the upregulation of cyclin E, with the ensuing arrest in the progression from G0/G1 to S phase of the cell cycle in glioma cells (Figure 7) .
It should be noted that the CKIs p27 and p21 can overcome the proliferative effects of an elevated concentration of cyclin D1 and D3 in glioma cells. Since a feature of glioma progression is the high levels of cyclin D1 and D3 (Chakrabarty et al., 1996; Cavalla et al., 1998; Zhang et al., 2005) , our results suggest that therapies that aim to upregulate p21 or p27 could reduce cell proliferation, despite the high levels of D-type cyclins.
Although these data contribute to understand the downstream pathways involved in the antiproliferative effect of Cx43 in glioma cells, the initial events leading to these changes remain to be elucidated. The Cx43CT interacts with c-Src, a non-receptor tyrosine kinase involved in the regulation of cell proliferation (Giepmans et al., 2001; Li et al., 2005; Gilleron et al., 2008) . Glioma cells exhibit a strong c-Src activity (Du et al., 2009) , which plays an important role in the transforming phenotype of these tumors (Weissenberger et al., 1997) . The most important result presented in this study is that restoring Cx43 to glioma cells diminishes the oncogenic activity of c-Src as judged by the decrease in the active form (Y416 c-Src) and the increase in the inactive form of c-Src (Y527 c-Src). When glioma cells pass from the G1 to S-phase of the cell cycle c-Src activity gradually increases, however Cx43 inhibits c-Src activity at the time that these cells should enter S-phase. It has been well documented that Cx43 increases the expression of p27 by impairing its degradation promoted by Skp2 (Zhang et al., 2003) . Accordingly, our data confirm that p27 expression is increased by Cx43 throughout the entire cell cycle. In addition, p27 phosphorylation by c-Src together with Skp2 regulates p27 proteolysis (Chu et al., 2007; Grimmler et al., 2007) . Consequently, the inhibition of c-Src promoted by Cx43 could also serve to upregulate p27 expression and activity, ultimately inhibiting the upregulation of cyclin E and therefore, the passage from G1 to S phase of the cell cycle ( Figure 7) .
Finally, by using a Cx43 mutant in which Tyr247 and Tyr265 were substituted by phenylalanines, we show that these Tyr residues in Cx43 are required to inhibit c-Src activity and the ensuing events involved in the inhibition of cell proliferation. Indeed, the loss of these residues prevents the inhibition of cyclin E expression and the upregulation of p27 that takes place when glioma cells progress from G1 to S-phase of the cell cycle. The effect of a similar Cx43 mutant (Y247F and Y265F) was previously studied in cells transformed with v-Src (Warn-Cramer et al., 2003; Lin et al., 2006) . However, no difference was found between the effects of Cx43 and the mutant Cx43 on the oncogenic activity of v-Src. In fact, Cx43 did not modify the exacerbated growth rate of cells transformed with v-Src. Although v-Src is nearly identical to c-Src, it lacks the carboxyl terminal region containing Tyr-527 that switches off its activity upon phosphorylation and Figure 7 Model to illustrate the molecular mechanism by which Cx43 arrests the cell cycle at the G1 phase in C6 glioma cells. (a) Glioma cells with low Cx43 expression and high c-Src activity (Y414 c-Src). The activity of c-Src promotes the proteolysis of p27, a cyclin dependent kinase (CDK) inhibitor. Consequently, the activity of CDK4/6 is high and it phosphorylates the retinoblastoma protein (pRb), which causes the release of E2F, a transcription factor that regulates several genes, such as cyclin E. This cyclin binds to and activates CDK2, which is required for the cell to pass from G1 to S-phase (Ohtani et al., 1995; Geng et al., 1996) . (b) Restoring Cx43 in glioma cells reduces the oncogenic activity of c-Src (Y416 c-Src) since Cx43 acts as a substrate for this kinase. Since degradation of p27 is reduced, the amount of this CDK inhibitor is increased. Consequently, pRb phosphorylation is reduced and the levels of cyclin E are downregulated, causing the arrest of cell cycle at the G1 phase.
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S Herrero-González et al therefore, v-Src is constitutively active (Cooper et al., 1986) . Consequently, these results indicate that Cx43 inhibits c-Src, which could be pathologically activated in gliomas, but not the constitutively active v-Src. Our data shows that Tyr247 and Tyr265, which are residues located in the Cx43CT, are involved in the antiproliferative effect of this protein. In agreement with this, an antiproliferative effect of Cx43CT has already been reported (Dang et al., 2003) . The transfection of Cx43CT, a non-channel forming region, inhibits cell growth (Dang et al., 2003) , suggesting an independent effect of GJIC (Krutovskikh et al., 2000) . Accordingly, our results show that Cx43CT rescued the phenotype of Cx43 mutated on Tyr247 and Tyr265.
A new discovered group of gap junctions proteins that preferentially form hemichannels (Penuela et al., 2007) , the pannexins, have also been associated with suppressed tumor growth in gliomas (Lai et al., 2007 (Lai et al., , 2009 ). Interestingly, pannexin 1 function is modified by c-Src (Suadicani et al., 2009) , although the participation of this oncogene in the tumor suppressor effect of pannexins remains to be elucidated.
In conclusion, our data indicate that Cx43 reduces the oncogenic activity of c-Src by acting as a substrate for this kinase, contributing to the reduction in the rate of proliferation, which is possibly an initial step in the antiproliferative effect of Cx43 in glioma cells. Although the ability of c-Src to phosphorylate Cx43 and inhibit GJIC is well known, this study provides the first evidence indicating that Cx43 can also inhibit c-Src activity. Therefore, we propose that there is a reciprocal interaction between Cx43 and c-Src activity, whereby Cx43 and c-Src are mutually regulated by a phosphorylation/dephosphorylation loop. It has recently been shown that the activity of c-Src is specifically elevated in malignant gliomas (Du et al., 2009) . Therefore, the results presented in this study showing that Cx43 inhibits the strong oncogenic activity of c-Src could help to design new therapies against gliomas.
Materials and methods
The materials and some methods are specified in detail in the supplementary information.
Cell cultures C6 glioma cells (ATTC) were cultured in DMEM supplemented with 10% (v/v) FCS, penicillin G (50 U/ml), streptomycin (37.5 U/ml) and amphotericin B (10 À4 mg/ml). Cells were plated on Petri dishes coated with poly-L-lysine. The cells were maintained at 37 1C in an atmosphere of 95% air/5% CO 2 and with 90-95% humidity.
Plasmid constructs and cell transfection
The pIRES-Cx43 and pIRES-Cx43CT (residues 232-382 of Cx43) constructs were generated by ligating a PCR-amplified fragment encoding the rat Cx43 or Cx43CT sequence (accession number: NM_012567) into the XhoI-BamHI sites of the bicistronic pIRES2-DsRed2 vector that encodes the red fluorescent protein. The fragment encoding the rat Cx43 sequence was obtained by RT-PCR performed on a template of total RNA isolated from rat astrocytes using the following primers: pIRES-Cx43: 5 0 -cgctcgagcgatgggtgactggagtg-3 0 and 5 0 -cggga tcccgttaaatctccaggtca-3 0 ; pIRES-Cx43CT: 5 0 -atgttcttcaaaggcg ttaaggatcg-3 0 and 5 0 -cgctcgagcgatgttcttcaaaggcg-3 0 . The Cx43Y247F/Y265F mutation was introduced into pIRES-Cx43 by site-directed mutagenesis using 5 0 oligonucleotides (5 0 -gaagaagcgatcctttccacgccaccactgg-3 0 and 5 0 -tgcggatctc caaaattcgctacttcaatgg-3 0 ) and the 3 0 oligonucleotides (5 0 -ccag tggtggcgtggaaaggatcgcttctt-3 0 and 5 0 -ccattgaagtaggcgattttggag atccgca-3 0 ). C6 glioma cells were transfected with the construct containing Cx43 (C6-Cx43), mutant Cx43 (C6-Cx43Y247F/ Y265F), mutant Cx43 plus Cx43CT (C6-Cx43Y247F/ Y265F þ CT), with the empty vector (C6-Ires) or with mutant Cx43 plus the empty vector (C6-Cx43Y247F/Y265F þ Ires) using lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, Barcelona, Spain). Transfected cells were selected at low density with G418 (0.5 mg/ml) in DMEM supplemented with 10% (v/v) FCS. The transfected clones were selected and amplified in the same culture medium
Transfection of siRNA C6-Cx43 clone 7 cells were transfected with a validated nontargeting siRNA (NT-siRNA) or with a siRNA specific for Cx43 (Cx43-siRNA) as previously reported (Herrero-Gonzalez et al., 2009 and Supplementary information).
Assessment of gap junctional intercellular communication
Gap junction permeability was determined by the scrapeloading/dye transfer technique (El-Fouly et al., 1987) adapted to our experimental conditions (Tabernero et al., 1996) . Scrape-loading was performed by scraping the cell layer with a broken razor blade in a Ca 2 þ -free ionic solution containing Lucifer yellow (1 mg/ml) and rhodaminde dextran (1 mg/ml). Lucifer yellow is a low molecular weight (457 Da) fluorescent dye that can pass through the gap junctions of loaded cells to their neighbors, while rhodamine dextran is a high molecular weight (10 000 Da) fluorescent dye that remains confined to the initially loaded cells. After 2 min, the dye solution was removed and the cells were carefully washed. Subsequently, 8 min after scraping, fluorescence photomicrographs were captured with a digital video camera (Leica DC100, Leica, Wetzlar, Germany) connected to an inverted fluorescent microscope equipped with the appropriate filters (Diaphot, Nikon). At least six photomicrographs of the centre of the dish were taken and the fluorescent area occupied by Lucifer yellow in the images was measured with the image-analyzer software (Scion Image, Scion Corporation, Frederick, MD, USA).
Western blotting
Western blotting was performed as described previously (Herrero-Gonzalez et al., 2009) . Primary antibodies were: Cx43 (1:250); cyclin D1 (1:500); cyclin D3 (1:100); p27 (1:100); p21 (1:250); pRb (1:100); cyclin E (1:500); total c-Src (1:500); Y416 c-Src (1:500), Y527 c-Src (1:250), GAPDH (1:3000) or alpha-actinin (1:1000). The intensity of the bands was analyzed using image-analyzer software (Scion Image) and the results were normalized according to the loading control values.
MTT assay
Cells cultured at 37 1C in 24-well-plates were incubated in the dark for 75 min with 300 ml/ml of PBS containing 0.5 mg/ml MTT. The medium was then removed and the cells were Connexin43 inhibits c-Src S Herrero-González et al incubated for 10 min in the dark with dimethyl sulfoxide (500 ml/ well) with mild shaking. Finally, the absorbance was measured at a wavelength of 570 nm using a microplate reader (Multiskan Ascent, Thermo Electron Corporation, Waltham, MA, USA).
Flow cytometry cell cycle analysis Cells were harvested and resuspended in DMEM at a concentration of 1 Â 10 6 cells/ml. The cells were fixed with 70% cold ethanol and stored at À20 1C overnight, and they were then washed with cold PBS and centrifuged. The cells were resuspended in 1 ml PBS containing RNase (0.25 mg/ml) and propidium iodide (5 mg/ml) and incubated at room temperature for 1 h. At least 20 000 events were analyzed for each experiment on a FACScan flow cytometer (Becton Dickinson). Accordingly, the percentages of cells within the various phases of the cell cycle were calculated using 'Paint-agate' software by gating G0/G1, S, and G2/M cell populations.
Cell cycle synchronization Cells were synchronized in the G0/G1 phase of the cell cycle by replacing the DMEM þ 10% FCS with DMEM without FCS for 60 h. For the cells to progress through the cell cycle, 10% FCS was again added to the media, and the cells were harvested at different times and the cell cycle analyzed.
Statistical analyses
The results are the means ± s.e.m. of at least three independent experiments. Statistical analyses were carried out with the Student's t-test to compare two groups and with One-Way ANOVA followed by the Bonferroni post-test when comparing more than two groups. Values were considered significant when Po0.05.
